6505--Ambrisentan Tablets (VA-26-00005803)

The Department of Veterans Affairs National Acquisition Center is seeking pharmaceutical prime vendor contractors to supply Ambrisentan Tablets in two strengths: 5mg and 10mg, with 30 tablets per bottle. This procurement will establish a five-year contract consisting of a base year plus four one-year option periods to serve the VA, Department of Defense, Bureau of Prisons, and Indian Health Service through VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must meet specific technical requirements including FDA approval, unique NDC numbers, and current Good Manufacturing Practices (cGMP) certification, with pricing submissions required to include a 0.5% Cost Recovery Fee for both the base year and all four option years. The contract will be awarded using a lowest-price technically acceptable evaluation methodology to a single contractor for both line items. Proposals are due by October 9, 2025, at 2:30 PM Central Time.

This solicitation does not utilize any set-aside designations and is open to all qualified contractors. The estimated annual requirements include 2,473 bottles of the 10mg strength tablets and 966 bottles of the 5mg strength tablets, totaling 3,439 bottles annually across both line items. The contract structure spans five years total, with the government anticipating one aggregate award covering both tablet strengths to streamline procurement and delivery operations. Distribution will occur through established pharmaceutical prime vendor networks serving multiple federal agencies and departments. No current incumbent contractor information or specific budget ranges were disclosed in the solicitation documentation.